Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ociperlimab (BGB-A1217)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BeiGene

Drug class:

TIGIT inhibitor

Related drugs:

PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2
PD-L1 expression	Esophageal Adenocarcinoma	PD-L1 expression	Esophageal Adenocarcinoma	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2
TIGIT expression	Esophageal Adenocarcinoma	TIGIT expression	Esophageal Adenocarcinoma	tislelizumab-jsgr + BGB-A1217 Sensitive: C3 – Early Trials tislelizumab-jsgr + BGB-A1217 Sensitive : C3	tislelizumab-jsgr + BGB-A1217 Sensitive: C3 – Early Trials tislelizumab-jsgr + BGB-A1217 Sensitive : C3
TIGIT expression	Esophageal Squamous Cell Carcinoma	TIGIT expression	Esophageal Squamous Cell Carcinoma	tislelizumab-jsgr + BGB-A1217 Sensitive: C3 – Early Trials tislelizumab-jsgr + BGB-A1217 Sensitive : C3	tislelizumab-jsgr + BGB-A1217 Sensitive: C3 – Early Trials tislelizumab-jsgr + BGB-A1217 Sensitive : C3